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========

In acute promyelocytic leukemia (APL), *PML-RARa* transcript is used as a marker for minimal residual disease (MRD), but the marker is not useful for pre-emptive management since its positivity directly indicates relapse. High Wilms' tumor gene 1 (*WT1*) expression was related with subsequent relapse in acute myeloid leukemia, and Hecht et al. recently reported that high initial *WT1* expression was associated with more relapse in APL \[[@CR1]--[@CR3]\].

We confirmed APL by chromosome analysis and *PML-RARα* reverse transcriptase polymerase chain reaction (RT-PCR) method. All were treated with idarubicin (12 mg/m^2^, days 1, 3, 5, and 7) and all-trans retinoic acid (ATRA; 45 mg/m^2^/day) \[[@CR4], [@CR5]\]. After achievement of hematological complete remission (CR), all received three courses of consolidation---first, idarubicin (7 mg/m^2^, days 1--4); second, mitoxantrone (10 mg/m^2^, days 1--4); and third, idarubicin (12 mg/m^2^, day 1--2)---followed by 2-year maintenance using 6-mercaptopurine (50 mg/m^2^/day) plus ATRA \[[@CR5]--[@CR7]\]. The molecular studies were performed at diagnosis and 1 month after chemotherapy, and every 3 months after maintenance. Quantification of *PML-RARα* and *WT1* were performed using the real-time quantitative (RQ)-PCR methods (Real-Q *PML-RARα* quantification kit, Biosewoom, Korea, and *WT1* ProfileQuant™ kit, Ipsogen, France) presenting a similar sensitivity of 4.5 log.

We initially identified 142 APL patients from 2009 to 2014 but finally focused on 117 patients (median age 44 years old (range 19--70 years)) who underwent at least 2 cycles of consolidation after hematological CR. All patients were in complete molecular response (CMR) at the time of enrollment (Additional file [1](#MOESM1){ref-type="media"}: Figure S1, Table [1](#Tab1){ref-type="table"}). Relapse was identified in 16 (13.7%) patients with a median duration of 22.8 months (range, 4.3--64.0). After median follow-up of 46.0 months (range, 14.7--86.3), 4-year cumulative incidence of relapse (CIR), non-relapse mortality (NRM), disease-free survival (DFS), and overall survival (OS) rates were 16.2, 1.2, 82.6, and 92.5%, respectively. We identified that high-risk Sanz-criteria, peak leukocyte count \>40.0 × 10^9^/L, and *FLT3* mutation were predictive for relapse.Table 1Baseline characteristics of enrolled patientsTotal *n* = 117Number or median valueAge, median (range)44 (19--70)Gender, male70 (59.8%)Laboratory findings at diagnosis Leukocyte count (×10^9^/L)2.68 (0.4--112.0)  Leukocytes count at peak (×10^9^/L)16.6 (0.4--112.0) Hemoglobin (g/dL)8.9 (4.0--15.0) Platelet (×10^9^/L)33.0 (5.0--163.0) Lactate dehydrogenase (LDH, U/L)692 (250--4070) Prothrombin time (PT, %)63.0 (35.0--101.0%) Partial thromboplastin time (aPTT, s)28.0 (20--45) Fibrinogen (mg/dL)134.0 (31.0--500.0) Antithrombin III (%)94.0 (49.0--150.0) D-dimer (mg/L)17.0 (1.0--36.0)Sanz criteria High64 (54.7%) Intermediate19 (16.2%) Low34 (29.1%)Karyotype Normal karyotype5 (4.3%) t(15;17) alone79 (67.5%) t(15;17) with 1 additional karyotype20 (17.1%) t(15;17) with ≥2 additional karyotype13 (11.1%)*PML-RARa* subtype BCR185 (72.6%) BCR332 (27.4%)*FLT3* mutation No *FLT3* mutation86 (73.5%)  *FLT3*-ITD25 (21.4%)  *FLT3*-TKD6 (5.1%)*WT1* (copies/10^4^ *ABL*), median (range) At diagnosis (*n* = 117)18330 (20.0--236160.0) Post-induction (*n* = 117)63.9 (4.9--2360.0) Post 1st consolidation (*n* = 117)66.2 (1.1--2320.0) Post 2nd consolidation (*n* = 117)80.1 (1.3--2110.0) Post 3rd consolidation (*n* = 117)71.9 (10.8--808.0)  ^a^Post-maintenance 3 months (*n* = 117)70.0 (6.0--5520.0)  ^a^Post-maintenance 1 year (*n* = 87)57.5 (10.0--1630.0)  ^a^Post-maintenance 2 year (*n* = 62)54.4 (10.0--500.0) At relapse (*n* = 16)239.5 (77.1--34910.0)Leukapheresis at initial treatment20 (17.1%)Differentiation syndrome21 (17.9%)Hematological complete response After induction115 (98.3%) After 2nd induction2 (1.7%)Complete molecular response (CMR) After induction68 (58.1%) After 2nd induction2 (1.7%) After 1st consolidation42 (35.9%) After 2nd consolidation5 (4.3%)*Abbreviation*: *BCR* breakpoint cluster region, *FLT3* Fms-related tyrosine kinase 3, *ITD* internal tandem duplication, *TKD* tyrosine kinase domain, *ABL* Abelson murine leukemia viral oncogene, *WT1*, Wilms tumor 1, *ATRA* all-trans retinoic acid, *AML* acute myeloid leukemia^a^Post-maintenance indicates the time from starting maintenance therapy

We compared the level of *WT1* between relapsed and non-relapsed group during the course of treatment (Additional file [1](#MOESM1){ref-type="media"}: Figure S2) and identified that median *WT1* was significantly different at post 2nd consolidation (171.5 vs. 76.3, *P* = 0.049), at post 3rd consolidation (156.0 vs. 67.6, *P* = 0.013) and at 3 months post-maintenance (162.0 vs. 59.1, *P* = 0.002). We found that *WT1* post-maintenance 3 months was the most significant parameter for relapse prediction at the cutoff of ≥120.0 copies/10^4^ *ABL*.

We calculated subsequent CIR and DFS rates in 116 patients after excluding 1 patient with early relapse. Patients with *WT1* post-maintenance 3 months higher than 120.0 copies/10^4^ *ABL* showed higher 4-year CIR (30.5 vs. 6.9%, *P* = 0.0002) and inferior 4-year DFS (62.8 vs. 91.4%, *P* \< 0.0001) rates (Fig. [1a, b](#Fig1){ref-type="fig"}). Also in the high-risk subgroup, high *WT1* post-maintenance 3 months showed higher 4-year CIR (43.3 vs. 11.1%, *P* \< 0.0001) and inferior 4-year DFS (55.5 vs. 86.4%, *P* = 0.0015) rates (Fig. [1c, d](#Fig1){ref-type="fig"}). In *FLT3* positive and negative subgroup, high *WT1* post-maintenance 3 months showed higher 4-year CIR (51.4 vs. 0.0%, *P* \< 0.0001 and 21.5 vs. 8.6%, *P* = 0.0434) and inferior 4-year DFS (46.7 vs. 100.0%, *P* = 0.0018 and 69.6 vs. 89.3%, *P* = 0.0154) rates (Fig. [1e, f](#Fig1){ref-type="fig"}).Fig. 1Treatment outcomes according to *WT1* expression level (\<120 vs. ≥120 copies/10^4^ *ABL*) at 3 months post-maintenance (PM-*WT1*). **a** Four-year CIR rates. **b** Four-year DFS rates. **c**, **d** Four-year CIR and DFS rates according to *WT1* expression level in the high-risk subgroup. **e**, **f** Four-year CIR and DFS rates according to the status of PM-*WT1* and *FLT3*-ITD mutation

Multivariate analysis (Additional file [1](#MOESM1){ref-type="media"}: Table S1) revealed that 4-year CIR was significantly higher in patients with high peak leukocyte count (HR = 6.414; 95% CI, 2.1--19.3, *P* \< 0.001) and high *WT1* post-maintenance 3 month (HR = 7.533; 95% CI, 2.3--24.8, *P* \< 0.001), and 4-year DFS was significantly inferior in patients with high peak leukocyte count (HR = 5.275; 95% CI, 1.9--14.7, *P* = 0.001) and high *WT1* post-maintenance 3 month (HR = 8.241; 95% CI, 2.3--29.1, *P* = 0.001).

Unfortunately, our chemotherapy regimen was not differently specified for high-risk APL and the standard treatment of APL is now changed to a combination therapy using ATO. Therefore, current results may not be applicable in the treatment course using ATO and another validation is needed. Conclusively, high post-remission *WT1* expression is a reliable marker for prediction of subsequent relapse in APL patients treated with conventional chemotherapy. For patients with high-risk of relapse, early intervention using *WT1-*specific therapy may prevent relapse and improve survival outcomes \[[@CR8], [@CR9]\].
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Additional file 1: Table S1.Multivariate analysis in APL patients with CMR. **Figure S1.** Consort diagram of enrolled patients in this study. Underlined patients were excluded in this study (n=25). Abbreviation: APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; CR, complete remission, CMR, complete molecular response; *WT1*, Wilms tumor 1. **Figure S2.** Comparison of *PML-RARa* and *WT1* expression levels between relapsed and non-relapsed patients from diagnosis to relapse or 1 year after starting maintenance for non-relapsed patients. (DOCX 152 kb)
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